Skip to main content
SpringerLink
Log in

Non-Hodgkin Lymphoma

  • Chapter
  • First Online:
Cancer in Adolescents and Young Adults

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies accounting for a significant portion of cancers occurring in children, adolescents, and young adults. The incidence increases with age as children grow into young adults. While there are greater than 30 distinct diagnostic NHL entities classified by the World Health Organization (WHO), five diseases account for >90 % of cases in CAYA—Burkitt lymphoma, lymphoblastic lymphoma, diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and primary mediastinal B-cell lymphoma. Other B-cell, T-cell, and NK-cell lymphomas have been described in CAYA, but the incidence is relatively low. Cure rates for CAYA with NHL range from 75 % to 90 % depending on risk stratification and are generally superior to outcomes in comparison to adult data. Inasmuch, there has been a paradigm shift to treat older adolescents and young adults on pediatric protocols, resulting in encouraging results. This chapter will review the clinical and biological characteristics of NHL occurring in CAYA, with particular focus on the nuances of disease in adolescents and young adults. The ultimate goal is to achieve the same excellent curative outcomes in adolescents and young adults that have been established in the pediatric literature.

Supported in part from grants the Pediatric Cancer Research Foundation, Marisa Fund, Hyundai Hope on Wheels, and the St. Baldrick’s Foundation (MSC).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bleyer WA, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival, 1975–2000. National Cancer Institute, Bethesda

    Google Scholar 

  2. Birch JM, Alston RD, Quinn M, Kelsey AM (2003) Incidence of malignant disease by morphological type, in young persons aged 12–24 years in England, 1979–1997. Eur J Cancer 39:2622–2631

    Article  CAS  PubMed  Google Scholar 

  3. Perkins SL, Raphael M, McCarthy K et al (2003) Pediatric mature B-cell lymphoma: distribution of lymphoma subtype varies between national groups. Results from the FAB/LMB96 International Cooperative Group Study. Blood 102:1428, ASH Annual Meeting Abstracts

    Article  CAS  Google Scholar 

  4. Tumours of haematopoietic and lymphoid tissues (2000) In: Jaffe E, Harris N, Stein H, Vardiman J (eds) World Health Organization classification of tumors. IARC Press, Washington, DC

    Google Scholar 

  5. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    CAS  PubMed  Google Scholar 

  6. Shipp MA, Ross KN, Tamayo P et al (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68–74

    Article  CAS  PubMed  Google Scholar 

  7. Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339

    CAS  PubMed  Google Scholar 

  8. Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS (2015) Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. doi:10.1200/JCO.2014.59.7203

    Google Scholar 

  9. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861

    Article  CAS  PubMed  Google Scholar 

  10. Ziepert M, Hasenclever D, Kuhnt E et al (2010) Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373–2380

    Article  CAS  PubMed  Google Scholar 

  11. Zhou Z, Sehn LH, Rademaker AW et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837–842

    Article  CAS  PubMed  Google Scholar 

  12. Cheson BD (2008) New response criteria for lymphomas in clinical trials. Ann Oncol 19(Suppl 4):iv35–iv38

    PubMed  Google Scholar 

  13. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578

    Article  PubMed  Google Scholar 

  14. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    Article  CAS  PubMed  Google Scholar 

  15. Moskowitz CH, Schoder H (2015) Current status of the role of PET imaging in diffuse large B-cell lymphoma. Semin Hematol 52:138–142

    Article  PubMed  Google Scholar 

  16. Duehrsen U, Hüttmann A, Müller S et al (2014) Positron emission tomography (PET) guided therapy of aggressive lymphomas- a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood 124:391, ASH Annual Meeting Abstracts

    Google Scholar 

  17. Sandlund JT, Guillerman RP, Perkins SL, Pinkerton CR, Rosolen A, Patte C, Reiter A, Cairo MS (2015) International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol. doi:10.1200/JCO.2014.59.0745

    Google Scholar 

  18. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11

    Article  PubMed  Google Scholar 

  19. Cairo MS, Coiffier B, Reiter A, Younes A (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586

    Article  CAS  PubMed  Google Scholar 

  20. Coiffier B, Mounier N, Bologna S et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21:4402–4406

    Article  CAS  PubMed  Google Scholar 

  21. Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS (2013) Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children’s Oncology Group Report. Br J Haematol 163:365–372

    Article  CAS  PubMed  Google Scholar 

  22. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998–3003

    Article  CAS  PubMed  Google Scholar 

  23. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS (2009) Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 144:24–40

    Article  PubMed  Google Scholar 

  24. Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miles RR, Arnold S, Cairo MS (2012) Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol 156:730–743

    Article  CAS  PubMed  Google Scholar 

  26. Kelly GL, Rickinson AB (2007) Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematol Am Soc Hematol Educ Program 2007:277–284

    Google Scholar 

  27. Reiter A, Klapper W (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 142:329–347

    Article  CAS  PubMed  Google Scholar 

  28. Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419–2430

    Article  CAS  PubMed  Google Scholar 

  29. Dave SS, Fu K, Wright GW et al (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354:2431–2442

    Article  CAS  PubMed  Google Scholar 

  30. Klapper W, Szczepanowski M, Burkhardt B et al (2008) Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 112:1374–1381

    Article  CAS  PubMed  Google Scholar 

  31. Cairo MS, Sposto R, Gerrard M et al (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 30:387–393

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin’s lymphoma in childhood. N Engl J Med 334:1238–1248

    Article  CAS  PubMed  Google Scholar 

  34. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG (2010) An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG-5961. Br J Haematol 148:600–610

    Article  PubMed  Google Scholar 

  35. Poirel HA, Cairo MS, Heerema NA et al (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 23:323–331

    Article  CAS  PubMed  Google Scholar 

  36. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS (2011) Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children’s oncology group report. Br J Haematol 153:758–763

    Article  PubMed  PubMed Central  Google Scholar 

  37. Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS (2015) Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children’s Oncology Group Pilot Study Report. Br J Haematol 170:367–71

    Article  PubMed  PubMed Central  Google Scholar 

  38. Cairo MS, Sposto R, Perkins SL et al (2003) Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol 120:660–670

    Article  PubMed  Google Scholar 

  39. Cairo MS, Gerrard M, Sposto R et al (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109:2736–2743

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS (2013) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia 27:1174–1177

    Article  CAS  PubMed  Google Scholar 

  41. Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS (2014) Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol 167:394–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Gerrard M, Cairo MS, Weston C et al (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141:840–847

    Article  CAS  PubMed  Google Scholar 

  43. Burkhardt B, Zimmermann M, Oschlies I et al (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39–49

    Article  PubMed  Google Scholar 

  44. Patte C, Auperin A, Michon J et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379

    Article  CAS  PubMed  Google Scholar 

  45. Hoelzer D, Walewski J, Dohner H et al (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124:3870–3879

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Magrath I, Adde M, Shad A et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934

    Article  CAS  PubMed  Google Scholar 

  47. Todeschini G, Tecchio C, Degani D et al (1997) Eighty-one percent event-free survival in advanced Burkitt’s lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8(Suppl 1):77–81

    Article  PubMed  Google Scholar 

  48. Perkins SL, Lones MA, Davenport V, Cairo MS (2003) B-cell non-Hodgkin’s lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children’s cancer group report. Clin Adv Hematol Oncol 1:314–317

    PubMed  Google Scholar 

  49. Meinhardt A, Burkhardt B, Zimmermann M et al (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 28:3115–3121

    Article  CAS  PubMed  Google Scholar 

  50. El-Mallawany NK, Cairo MS (2015) Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol 13:113–123

    PubMed  Google Scholar 

  51. Atra A, Gerrard M, Hobson R et al (2001) Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol 112:965–968

    Article  CAS  PubMed  Google Scholar 

  52. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52:177–181

    Article  PubMed  PubMed Central  Google Scholar 

  53. El-Mallawany NK, Cairo M (2014) Hematopoietic stem cell transplantation in children, adolescents and young adults. In: Savani B, Mohty M (eds) Clinical guide to transplantation in lymphoma. Wiley-Blackwell, Hoboken

    Google Scholar 

  54. Gross TG, Hale GA, He W, Camitta BM, Sander J, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang M-J, Davies SM, Eapen M (2010) Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 16:223–230

    Article  PubMed  Google Scholar 

  55. Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, Gross TG, Warkentin P, Vlachos A, Harrison L, Cairo MS (2011) Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant 17:249–258

    Article  PubMed  Google Scholar 

  56. Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS (2015) Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 29:448–455

    Article  CAS  PubMed  Google Scholar 

  57. Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88–94

    Article  CAS  PubMed  Google Scholar 

  58. Gopal AK, Kahl BS, de Vos S et al (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008–1018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS (2015) Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res 3:333–344

    Article  CAS  PubMed  Google Scholar 

  60. Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Awasthi A, Ayello J, van de Ven C, Hovy S, Cairo MS (2013) Obinutuzumab (GA101) significantly improves survival in CD20 positive pre-B cell lymphoblastic leukemia (pre-B-ALL) xenograft models compared to rituximab (RTX): potential targeted therapy in patients with high risk pre-B-ALL. Blood 122:3068, ASH Annual Meeting Abstracts

    Google Scholar 

  62. Dalle S, Reslan L, Besseyre de Horts T et al (2011) Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 10:178–185

    Article  CAS  PubMed  Google Scholar 

  63. Herter S, Herting F, Mundigl O et al (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 12:2031–2042

    Article  CAS  PubMed  Google Scholar 

  64. Morschhauser FA, Cartron G, Thieblemont C et al (2013) Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31:2912–2919

    Article  CAS  PubMed  Google Scholar 

  65. Salles G, Morschhauser F, Lamy T et al (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119:5126–5132

    Article  CAS  PubMed  Google Scholar 

  66. Reiter A, Schrappe M, Tiemann M et al (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94:3294–3306

    CAS  PubMed  Google Scholar 

  67. Cairo MS, Sposto R, Hoover-Regan M et al (2003) Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 72:53–63

    Article  PubMed  Google Scholar 

  68. Laver JH, Mahmoud H, Pick TE et al (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin’s lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105–109

    Article  PubMed  Google Scholar 

  69. Patte C, Auperin A, Bergeron C et al (2002) Large B- cell lymphoma (LBCL) in children: similarities and differences with Burkitt (BL) in children and LBCL in adults. Experience of the SFOP LMB89 study. Ann Oncol 13:110, abstract #379

    Article  Google Scholar 

  70. Laver J, Weinstein H, Hutchinson R et al (2001) Lineage-specific differences in outcome for advanced stage large cell lymphoma in children and adolescents: results of a randomized phase III Pediatric Oncology Group Trial. Blood 98:345a, ASH Annual Meeting Abstracts

    Google Scholar 

  71. Recher C, Coiffier B, Haioun C et al (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378:1858–1867

    Article  CAS  PubMed  Google Scholar 

  72. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  73. Cunningham D, Hawkes EA, Jack A et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381:1817–1826

    Article  CAS  PubMed  Google Scholar 

  74. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    Article  CAS  PubMed  Google Scholar 

  75. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) N Engl J Med 329:987–994

    Google Scholar 

  76. Pfreundschuh M, Kuhnt E, Trumper L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013–1022

    Article  CAS  PubMed  Google Scholar 

  77. Hohloch K, Zeynalova S, Held G et al (2014) Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens. Leukemia 28:2260–2263

    Article  CAS  PubMed  Google Scholar 

  78. Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–2323

    Article  CAS  PubMed  Google Scholar 

  79. Wilson WH (2013) Treatment strategies for aggressive lymphomas: what works? Hematol Am Soc Hematol Educ Program 2013:584–590

    Google Scholar 

  80. Barrans SL, Crouch S, Care MA et al (2012) Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol 159:441–453

    Article  CAS  PubMed  Google Scholar 

  81. Stiff PJ, Unger JM, Cook JR et al (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 369:1681–1690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Vitolo U, Chiappella A, Brusamolino E et al (2012) Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC + ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2–3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL). ASH annual meeting abstracts 120:688

    Google Scholar 

  83. Pfreundschuh M, Zwick C, Zeynalova S et al (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol 19:545–552

    Article  CAS  PubMed  Google Scholar 

  84. Holte H, Leppa S, Bjorkholm M et al (2013) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 24:1385–1392

    Article  CAS  PubMed  Google Scholar 

  85. McMillan A, Rule S, Patmore R et al (2015) (abstract). Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3–5) yields a good outcome without transplantation: a Phase 2 UK NCRI/LLR Trial. In: 13th International conference on malignant lymphoma, Lugano. p 130

    Google Scholar 

  86. Nowakowski GS, LaPlant B, Macon WR et al (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 33:251–257

    Article  CAS  PubMed  Google Scholar 

  87. van Imhoff GW, McMillan A, Matasar MJ et al (2014) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd Study (OMB110928)

    Google Scholar 

  88. Illidge TM (2012) Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations. Expert Opin Biol Ther 12:543–545

    Article  CAS  PubMed  Google Scholar 

  89. Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110

    Article  CAS  PubMed  Google Scholar 

  90. Aukema SM, Siebert R, Schuuring E et al (2011) Double-hit B-cell lymphomas. Blood 117:2319–2331

    Article  CAS  PubMed  Google Scholar 

  91. Deffenbacher KE, Iqbal J, Sanger W et al (2012) Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 119:3757–3766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Gerrard M, Waxman IM, Sposto R, Auperin A, Perkins SL, Goldman S, Harrison L, Pinkerton R, McCarthy K, Raphael M, Patte C, Cairo MS (2013) Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 121:278–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118:2659–2669

    Article  CAS  PubMed  Google Scholar 

  94. Dunleavy K, Pittaluga S, Maeda LS et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408–1416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Woessmann W, Lisfeld J, Burkhardt B (2013) Therapy in primary mediastinal B-cell lymphoma. N Engl J Med 369:282

    Article  PubMed  Google Scholar 

  96. Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

    Google Scholar 

  97. Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785

    Article  CAS  PubMed  Google Scholar 

  98. Mussolin L, Pillon M, d’Amore ES et al (2005) Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia 19:1643–1647

    Article  CAS  PubMed  Google Scholar 

  99. Savage KJ, Harris NL, Vose JM et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496–5504

    Article  CAS  PubMed  Google Scholar 

  100. Lamant L, McCarthy K, d’Amore E et al (2011) Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 29:4669–4676

    Article  PubMed  Google Scholar 

  101. Stein H, Foss HD, Durkop H et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695

    CAS  PubMed  Google Scholar 

  102. Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284

    Article  CAS  PubMed  Google Scholar 

  103. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11–23

    Article  CAS  PubMed  Google Scholar 

  104. Boi M, Zucca E, Inghirami G, Bertoni F (2015) Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol 168:771–783

    Article  CAS  PubMed  Google Scholar 

  105. Wan W, Albom MS, Lu L et al (2006) Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107:1617–1623

    Article  CAS  PubMed  Google Scholar 

  106. Falini B, Pileri S, Zinzani PL et al (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697–2706

    CAS  PubMed  Google Scholar 

  107. Oschlies I, Lisfeld J, Lamant L et al (2013) ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica 98:50–56

    Article  PubMed  PubMed Central  Google Scholar 

  108. Pulford K, Falini B, Banham AH et al (2000) Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96:1605–1607

    CAS  PubMed  Google Scholar 

  109. Chiarle R, Martinengo C, Mastini C et al (2008) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14:676–680

    Article  CAS  PubMed  Google Scholar 

  110. Ait-Tahar K, Cerundolo V, Banham AH et al (2006) B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 118:688–695

    Article  CAS  PubMed  Google Scholar 

  111. Ciambotti B, Mussolin L, d’Amore ES et al (2014) Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma. J Pediatr Hematol Oncol 36:e359–e365

    Article  CAS  PubMed  Google Scholar 

  112. Laver JH, Kraveka JM, Hutchison RE et al (2005) Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 23:541–547

    Article  CAS  PubMed  Google Scholar 

  113. Lowe EJ, Sposto R, Perkins SL et al (2009) Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer 52:335–339

    Article  PubMed  PubMed Central  Google Scholar 

  114. Brugieres L, Le Deley MC, Rosolen A et al (2009) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 27:897–903

    Article  CAS  PubMed  Google Scholar 

  115. Alexander S, Kraveka JM, Weitzman S et al (2014) Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children’s oncology group. Pediatr Blood Cancer 61:2236–2242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Gascoyne RD, Aoun P, Wu D et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921

    CAS  PubMed  Google Scholar 

  117. Suzuki R, Kagami Y, Takeuchi K et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000

    CAS  PubMed  Google Scholar 

  118. Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–3425

    Article  CAS  PubMed  Google Scholar 

  119. Sibon D, Fournier M, Briere J et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30:3939–3946

    Article  PubMed  Google Scholar 

  120. Deconinck E, Lamy T, Foussard C et al (2000) Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 109:736–742

    Article  CAS  PubMed  Google Scholar 

  121. Brugieres L, Deley MC, Pacquement H et al (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598

    CAS  PubMed  Google Scholar 

  122. Mori T, Kiyokawa N, Shimada H, Miyauchi J, Fujimoto J (2003) Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol 121:94–96

    Article  PubMed  Google Scholar 

  123. Pillon M, Gregucci F, Lombardi A et al (2012) Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer 59:828–833

    Article  PubMed  Google Scholar 

  124. Reiter A, Schrappe M, Tiemann M et al (1994) Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12:899–908

    Article  CAS  PubMed  Google Scholar 

  125. Rosolen A, Pillon M, Garaventa A et al (2005) Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 104:2133–2140

    Article  CAS  PubMed  Google Scholar 

  126. Seidemann K, Tiemann M, Schrappe M et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97:3699–3706

    Article  CAS  PubMed  Google Scholar 

  127. Williams DM, Hobson R, Imeson J et al (2002) Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 117:812–820

    Article  CAS  PubMed  Google Scholar 

  128. Le Deley MC, Rosolen A, Williams DM et al (2010) Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 28:3987–3993

    Article  PubMed  CAS  Google Scholar 

  129. Attarbaschi A, Mann G, Rosolen A et al (2011) Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma. Blood 117:5616–5619

    Article  CAS  PubMed  Google Scholar 

  130. Sandlund JT, Pui CH, Santana VM et al (1994) Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin’s lymphoma. J Clin Oncol 12:895–898

    Article  CAS  PubMed  Google Scholar 

  131. Zelenetz AD (2014) Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. J Natl Compr Canc Netw 12:797–800

    Article  PubMed  Google Scholar 

  132. ten Berge RL, Dukers DF, Oudejans JJ et al (1999) Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 93:2688–2696

    PubMed  Google Scholar 

  133. Le Deley MC, Reiter A, Williams D et al (2008) Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 111:1560–1566

    Article  PubMed  CAS  Google Scholar 

  134. Damm-Welk C, Busch K, Burkhardt B et al (2007) Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 110:670–677

    Article  CAS  PubMed  Google Scholar 

  135. Damm-Welk C, Mussolin L, Zimmermann M et al (2014) Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 123:334–337

    Article  CAS  PubMed  Google Scholar 

  136. Ait-Tahar K, Damm-Welk C, Burkhardt B et al (2010) Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 115:3314–3319

    Article  CAS  PubMed  Google Scholar 

  137. Mussolin L, Damm-Welk C, Pillon M et al (2013) Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 27:416–422

    Article  CAS  PubMed  Google Scholar 

  138. Brugieres L, Pacquement H, Le Deley MC et al (2009) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 27:5056–5061

    Article  CAS  PubMed  Google Scholar 

  139. Brugieres L, Quartier P, Le Deley MC et al (2000) Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children – a report from the French Society of Pediatric Oncology. Ann Oncol 11:53–58

    Article  CAS  PubMed  Google Scholar 

  140. Fukano R, Mori T, Kobayashi R et al (2015) Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol 168:557–563

    Article  PubMed  Google Scholar 

  141. Mori T, Takimoto T, Katano N et al (2006) Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol 132:594–597

    Article  PubMed  Google Scholar 

  142. Strullu M, Thomas C, Le Deley MC et al (2015) Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant 50:795–801

    Article  CAS  PubMed  Google Scholar 

  143. Woessmann W, Peters C, Lenhard M et al (2006) Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Munster group report. Br J Haematol 133:176–182

    Article  PubMed  Google Scholar 

  144. Woessmann W, Zimmermann M, Lenhard M et al (2011) Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 29:3065–3071

    Article  PubMed  Google Scholar 

  145. Woessman W, Brugieres L, Rosolen A, Williams D (2012) Risk-adapted therapy for patients with relapsed or refractory ALCL – interim-results of the prospective EICNHL-Trial ALCL-relapse Br J Haematol 159:41

    Google Scholar 

  146. Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196

    Article  CAS  PubMed  Google Scholar 

  147. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  CAS  PubMed  Google Scholar 

  148. Mosse YP, Lim MS, Voss SD et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14:472–480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Gambacorti Passerini C, Farina F, Stasia A et al (2014) Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 106:djt378

    Article  PubMed  CAS  Google Scholar 

  150. Lovisa F, Cozza G, Cristiani A et al (2015) ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. PLoS One 10:e0121378

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  151. Barcos MGP, Lukes RJ (1975) Malignant lymphoma of the convoluted lymphocytes: a new entity of possible T-cell type. In: Sinks L, Godden J (eds) Conflicts in childhood cancer: an evaluation of current management. Liss, New York, p 147

    Google Scholar 

  152. Amylon MD, Shuster J, Pullen J et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335–342

    Article  CAS  PubMed  Google Scholar 

  153. Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98:1283–1291

    Article  PubMed  Google Scholar 

  154. Reiter A, Schrappe M, Ludwig WD et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421

    CAS  PubMed  Google Scholar 

  155. Tubergen DG, Krailo MD, Meadows AT et al (1995) Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Childrens Cancer Group study. J Clin Oncol 13:1368–1376

    Article  CAS  PubMed  Google Scholar 

  156. Colgan JP, Andersen J, Habermann TM et al (1994) Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin’s lymphoma. Leuk Lymphoma 15:291–296

    Article  CAS  PubMed  Google Scholar 

  157. Thomas DA, Kantarjian HM (2001) Lymphoblastic lymphoma. Hematol Oncol Clin North Am 15:51–95, vi

    Article  CAS  PubMed  Google Scholar 

  158. Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, Lones MA, Gross TG, Cairo MS, Perkins SL (2012) The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children’s Oncology Group report. Br J Haematol 159:454–461

    Article  PubMed  PubMed Central  Google Scholar 

  159. Cairo MS, Raetz E, Perkins SL (2003) Non-Hodgkin lymphoma in children. In: Kufe DW, Pollock RE, Weischselbaum RR (eds) Cancer medicine. Decker, London

    Google Scholar 

  160. Perkins SL (2000) Work-up and diagnosis of pediatric non-Hodgkin’s lymphomas. Pediatr Dev Pathol 3:374–390

    Article  CAS  PubMed  Google Scholar 

  161. Coustan-Smith E, Mullighan CG, Onciu M et al (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147–156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Zhang J, Ding L, Holmfeldt L et al (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Pilozzi E, Muller-Hermelink HK, Falini B et al (1999) Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267–270

    Article  CAS  PubMed  Google Scholar 

  164. Hojo H, Sasaki Y, Nakamura N, Abe M (2001) Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence. Am J Clin Pathol 116:673–682

    Article  CAS  PubMed  Google Scholar 

  165. Raetz EA, Perkins SL, Bhojwani D et al (2006) Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 47:130–140

    Article  PubMed  Google Scholar 

  166. Baelydier F (2009) NOTCH1/FBXW7 mutational status differs qualitatively and quantitatively in T-lineage lymphoblastic lymphoma (T-LL) and leukemi (T-ALL). Hematol Meet Rep 3:34

    Google Scholar 

  167. Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB (1990) Results of treatment of childhood localized non-Hodgkin’s lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 322:1169–1174

    Article  CAS  PubMed  Google Scholar 

  168. Anderson JR, Jenkin RD, Wilson JF et al (1993) Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11:1024–1032

    Article  CAS  PubMed  Google Scholar 

  169. Asselin B, Shuster JJ, Amylon M et al (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 20:1464, abstract

    Google Scholar 

  170. Burkhardt B, Woessmann W, Zimmermann M et al (2006) Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24:491–499

    Article  PubMed  Google Scholar 

  171. Woessmann W, Seidemann K, Mann G et al (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105:948–958

    Article  CAS  PubMed  Google Scholar 

  172. Hoelzer D, Gokbuget N, Digel W et al (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379–4385

    Article  CAS  PubMed  Google Scholar 

  173. Wollner N, Burchenal JH, Lieberman PH et al (1976) Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer 37:123–134

    Article  CAS  PubMed  Google Scholar 

  174. Anderson JR, Wilson JF, Jenkin DT et al (1983) Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559–565

    Article  CAS  PubMed  Google Scholar 

  175. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS (2008) Shortened intensified multiagent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol 143:261–267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Eden OB, Hann I, Imeson J et al (1992) Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children’s Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 82:310–316

    Article  CAS  PubMed  Google Scholar 

  177. Hvizdala EV, Berard C, Callihan T et al (1988) Lymphoblastic lymphoma in children – a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group study. J Clin Oncol 6:26–33

    Article  CAS  PubMed  Google Scholar 

  178. Millot F, Suciu S, Philippe N et al (2001) Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935–1942

    Article  CAS  PubMed  Google Scholar 

  179. Reiter A, Schrappe M, Parwaresch R et al (1995) Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage – a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 13:359–372

    Article  CAS  PubMed  Google Scholar 

  180. Weinstein HJ, Cassady JR, Levey R (1983) Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1:537–541

    Article  CAS  PubMed  Google Scholar 

  181. Coleman CN, Picozzi VJ Jr, Cox RS et al (1986) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637

    Article  CAS  PubMed  Google Scholar 

  182. Morel P, Lepage E, Brice P et al (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085

    Article  CAS  PubMed  Google Scholar 

  183. Zinzani PL, Bendandi M, Visani G et al (1996) Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 23:577–582

    Article  CAS  PubMed  Google Scholar 

  184. Bouabdallah R, Xerri L, Bardou VJ et al (1998) Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 9:619–625

    Article  CAS  PubMed  Google Scholar 

  185. Sweetenham JW, Santini G, Qian W et al (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927–2936

    Article  CAS  PubMed  Google Scholar 

  186. Levine JE, Harris RE, Loberiza FR Jr et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482

    Article  CAS  PubMed  Google Scholar 

  187. Burkhardt B, Reiter A, Landmann E et al (2009) Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster Group. J Clin Oncol 27:3363–3369

    Article  PubMed  Google Scholar 

  188. Berg SL, Blaney SM, Devidas M et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 23:3376–3382

    Article  CAS  PubMed  Google Scholar 

  189. Whitlock J, dalla Pozza L, Goldberg J et al (2014) Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL). Blood 124

    Google Scholar 

  190. Kim SJ, Yoon DH, Kang HJ et al (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 48:3223–3231

    Article  CAS  PubMed  Google Scholar 

  191. Messinger YH, Gaynon PS, Sposto R et al (2012) Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood 120:285–290

    Article  CAS  PubMed  Google Scholar 

  192. Dunleavy K, Pittaluga S, Czuczman MS et al (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069–6076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Ruan J, Martin P, Furman RR et al (2011) Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690–697

    Article  CAS  PubMed  Google Scholar 

  194. Blaney SM, Bernstein M, Neville K et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study (ADVL0015). J Clin Oncol 22:4804–4809

    Article  CAS  PubMed  Google Scholar 

  195. Frazer JK, Meeker ND, Rudner L et al (2009) Heritable T-cell malignancy models established in a zebrafish phenotypic screen. Leukemia 23:1825–1835

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds.) (2008) WHO classification of tumors of the haematopoietic and lymphoid tissues. IARC, Lyon

    Google Scholar 

  197. Lorsbach RB, Shay-Seymore D, Moore J et al (2002) Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 99:1959–1964

    Article  CAS  PubMed  Google Scholar 

  198. Oschlies I, Salaverria I, Mahn F et al (2010) Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma – Berlin – Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 95:253–259

    Article  PubMed  Google Scholar 

  199. Al-Tourah AJ, Gill KK, Chhanabhai M et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26:5165–5169

    Article  PubMed  Google Scholar 

  200. Montoto S, Davies AJ, Matthews J et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426–2433

    Article  PubMed  Google Scholar 

  201. El-Mallawany NK, Frazer JK, Van Vlierberghe P, Ferrando AA, Perkins S, Lim M, Chu Y, Cairo MS (2012) Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. Blood Cancer J 2:e65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Hutchison RE, Laver JH, Chang M et al (2008) Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: a Children’s Oncology Group study. Pediatr Blood Cancer 51:29–33

    Article  PubMed  PubMed Central  Google Scholar 

  203. Kobayashi R, Yamato K, Tanaka F et al (2010) Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer 54:212–215

    PubMed  Google Scholar 

  204. Kontny U, Oschlies I, Woessmann W et al (2015) Non-anaplastic peripheral T-cell lymphoma in children and adolescents – a retrospective analysis of the NHL-BFM study group. Br J Haematol 168:835–844

    Article  CAS  PubMed  Google Scholar 

  205. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  PubMed  Google Scholar 

  206. Yamaguchi M, Kwong YL, Kim WS et al (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416

    Article  CAS  PubMed  Google Scholar 

  207. O’Connor OA, Horwitz S, Hamlin P et al (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357–4364

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  208. Dearden CE, Johnson R, Pettengell R et al (2011) Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 153:451–485

    Article  PubMed  Google Scholar 

  209. Fanale MA, Horwitz SM, Forero-Torres A et al (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32:3137–3143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Ogura M, Ishida T, Hatake K et al (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32:1157–1163

    Article  CAS  PubMed  Google Scholar 

  211. Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31:3100–3109

    Article  PubMed  PubMed Central  Google Scholar 

  212. Kim SW, Yoon SS, Suzuki R et al (2013) Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia 27:1394–1397

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Erin Morris, RN, for her expert editorial assistance in the preparation of this chapter.

Author information

Authors and Affiliations

  1. Departments of Pediatrics, New York Medical College, Valhalla, NY, USA

    Jessica Hochberg MD, Nader Kim El-Mallawany MD & Mitchell S. Cairo MD

  2. Department of Pediatrics, Institut Gustave Roussy, Villejuif, France

    Laurence Brugieres MD

  3. Department of Hematology, Nottingham University Hospitals NHS Trust, Nottingham, UK

    Andrew McMillan MD

  4. Departments of Medicine, New York Medical College, Valhalla, NY, USA

    Mitchell S. Cairo MD

  5. Departments of Pathology, New York Medical College, Valhalla, NY, USA

    Mitchell S. Cairo MD

  6. Departments of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA

    Mitchell S. Cairo MD

  7. Departments of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA

    Mitchell S. Cairo MD

Authors
  1. Jessica Hochberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nader Kim El-Mallawany MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Brugieres MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew McMillan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitchell S. Cairo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica Hochberg MD .

Editor information

Editors and Affiliations

  1. Bend, Oregon, USA

    Archie Bleyer

  2. McMaster University, Hamilton, Ontario, Canada

    Ronald Barr

  3. RiesSearch LLC, Rockville, Maryland, USA

    Lynn Ries

  4. University College Hospital, London, United Kingdom

    Jeremy Whelan

  5. Pediatric Oncology Unit, National Tumor Institute, Milano, Italy

    Andrea Ferrari

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing

About this chapter

Cite this chapter

Hochberg, J., El-Mallawany, N.K., Brugieres, L., McMillan, A., Cairo, M.S. (2017). Non-Hodgkin Lymphoma. In: Bleyer, A., Barr, R., Ries, L., Whelan, J., Ferrari, A. (eds) Cancer in Adolescents and Young Adults. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-33679-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33679-4_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33677-0

  • Online ISBN: 978-3-319-33679-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation